Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. 2005

Shiqing Li, and Karl R Schmitz, and Philip D Jeffrey, and Jed J W Wiltzius, and Paul Kussie, and Kathryn M Ferguson
Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.

Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and inhibition of these receptors. Here we describe the 2.8 angstroms resolution X-ray crystal structure of the antigen binding (Fab) fragment from cetuximab (Erbitux), an inhibitory anti-EGFR antibody, in complex with the soluble extracellular region of EGFR (sEGFR). The sEGFR is in the characteristic "autoinhibited" or "tethered" inactive configuration. Cetuximab interacts exclusively with domain III of sEGFR, partially occluding the ligand binding region on this domain and sterically preventing the receptor from adopting the extended conformation required for dimerization. We suggest that both these effects contribute to potent inhibition of EGFR activation.

UI MeSH Term Description Entries
D007140 Immunoglobulin Fab Fragments Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN. Fab Fragment,Fab Fragments,Ig Fab Fragments,Immunoglobulins, Fab Fragment,Fab Immunoglobulin Fragments,Immunoglobulin Fab Fragment,Immunoglobulins, Fab,Fab Fragment Immunoglobulins,Fab Fragment, Immunoglobulin,Fab Fragments, Immunoglobulin,Fragment Immunoglobulins, Fab,Fragment, Fab,Immunoglobulin Fragments, Fab
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011940 Receptor Aggregation Chemically stimulated aggregation of cell surface receptors, which potentiates the action of the effector cell. Aggregation, Receptor,Capping, Receptor,Receptor Capping
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004815 Epidermal Growth Factor A 6-kDa polypeptide growth factor initially discovered in mouse submaxillary glands. Human epidermal growth factor was originally isolated from urine based on its ability to inhibit gastric secretion and called urogastrone. Epidermal growth factor exerts a wide variety of biological effects including the promotion of proliferation and differentiation of mesenchymal and EPITHELIAL CELLS. It is synthesized as a transmembrane protein which can be cleaved to release a soluble active form. EGF,Epidermal Growth Factor-Urogastrone,Urogastrone,Human Urinary Gastric Inhibitor,beta-Urogastrone,Growth Factor, Epidermal,Growth Factor-Urogastrone, Epidermal,beta Urogastrone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068818 Cetuximab A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors. C225,Erbitux,IMC C225,IMC-C225,MAb C225
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal

Related Publications

Shiqing Li, and Karl R Schmitz, and Philip D Jeffrey, and Jed J W Wiltzius, and Paul Kussie, and Kathryn M Ferguson
January 1989, Progress in growth factor research,
Shiqing Li, and Karl R Schmitz, and Philip D Jeffrey, and Jed J W Wiltzius, and Paul Kussie, and Kathryn M Ferguson
September 2013, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Shiqing Li, and Karl R Schmitz, and Philip D Jeffrey, and Jed J W Wiltzius, and Paul Kussie, and Kathryn M Ferguson
January 2006, The British journal of dermatology,
Shiqing Li, and Karl R Schmitz, and Philip D Jeffrey, and Jed J W Wiltzius, and Paul Kussie, and Kathryn M Ferguson
August 2009, Cancer research,
Shiqing Li, and Karl R Schmitz, and Philip D Jeffrey, and Jed J W Wiltzius, and Paul Kussie, and Kathryn M Ferguson
October 2022, Nucleic acid therapeutics,
Shiqing Li, and Karl R Schmitz, and Philip D Jeffrey, and Jed J W Wiltzius, and Paul Kussie, and Kathryn M Ferguson
February 1993, Biochemical and biophysical research communications,
Shiqing Li, and Karl R Schmitz, and Philip D Jeffrey, and Jed J W Wiltzius, and Paul Kussie, and Kathryn M Ferguson
October 2013, European journal of cancer (Oxford, England : 1990),
Shiqing Li, and Karl R Schmitz, and Philip D Jeffrey, and Jed J W Wiltzius, and Paul Kussie, and Kathryn M Ferguson
November 2012, Neoplasia (New York, N.Y.),
Shiqing Li, and Karl R Schmitz, and Philip D Jeffrey, and Jed J W Wiltzius, and Paul Kussie, and Kathryn M Ferguson
April 2016, Acta dermatovenerologica Croatica : ADC,
Shiqing Li, and Karl R Schmitz, and Philip D Jeffrey, and Jed J W Wiltzius, and Paul Kussie, and Kathryn M Ferguson
November 1993, The Journal of biological chemistry,
Copied contents to your clipboard!